Immunomodulatory effects of vitamin D: implications for GVHD

Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Adam Bissonnette(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Brett Glotzbecker(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Whitney Keefe(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Corrine Zarwan(Beth Israel Deaconess Medical Center), Zhiyou Wu(Dana-Farber Cancer Institute), Kristen E. Stevenson(Dana-Farber Cancer Institute), Heidi Mills(Beth Israel Deaconess Medical Center), D. Tzachanis(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Rehan Ahmad(Chinese Academy of Sciences)
Bone Marrow Transplantation
January 18, 2010
10.1038/bmt.2009.366
Cited by 43

Related Papers

PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
|Cell|2013|1.4k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k